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ABSTRACT: Three generations of pyrenyl bis-MPA den-
drimers with two diﬀerent end-groups, acetonide (pyrGn) o r 
alcohol (pyrGn‑OH) (n = 1−3), were synthesized, and the 
pyrenyl group of the dendritic molecules was encapsulated in 
the  arene  ruthenium  metal lacages ,  [Ru6 (p-cyme-
ne)6(OO∩OO)3(tpt)2]6+ (OO∩OO = 5,8-dioxydo-1,4-naph-
taquinonato (donq) [1]6+ and 6,11-dioxydo-5,12-naphtacene-
dionato (dotq) [2]6+; tpt =2,4,6-tri(pyridin-4-yl)-1,3,5-tria-
zine). The host−guest properties of [guest⊂1]6+ and 
[guest⊂2]6+ were studied in solution by NMR and UV−vis 
spectroscopic methods, thus allowing the determination of the 
aﬃnity constants. Moreover, the cytotoxicity of these water-
soluble host−guest systems and the pyrenyl-dendrimers was evaluated on human ovarian cancer cells.
■ INTRODUCTION
The synthesis of dendrimers with deﬁned structures is now well
established,1 employing divergent,2 convergent,3 and the
somewhat less exploited double-stage convergent4 routes.
Since these routes allow dendrimers to be prepared with
precise sizes and shapes, and since dendrimers are relatively
easy to functionalize,5 and possess other interesting properties,6
they have been studied as potential drug delivery vectors.
Water-soluble dendrimers have been shown to improve drug
solubility, increase drug circulation time, and prolong drug
residence in tumors, thus reducing toxicity.7 Biodegradability is
an important criteria in order to avoid cellular accumulation
leading to lysosomal storage disease in patients.8 Most
dendrimers are based on ester or amide linkages which degrade
by chemical hydrolysis or enzymatic cleavage under physio-
logical conditions.9 Some dendrimers are both water-soluble
and biodegradable such as poly(2,2-bis(hydroxymethyl)-
propionic acids (bisMPA),10 poly(L-lysine) dendrimers
(PLL),11 polyester structures (PGLSA−OH),12 and polyamido-
amine derivatives (PAMAM),2b among others.13 For example, a
fourth generation polyester dendron attached to a trisphenolic
core derived from the monomeric unit bis-MPA has been
evaluated for drug delivery applications.14 Cell proliferation
studies have suggested that the dendritic scaﬀold did not exhibit
a signiﬁcant toxic eﬀect. The attachment of poly(ethylene
glycol) to the surface of this type of dendrimer has also been
successful for therapeutic applications,10b,15 and structure−
activity relationships have shown that both generation and
steric eﬀect are important.7
Recently, we have reported the synthesis of host−guest
systems composed of water-soluble arene ruthenium metal-
laprisms and pyrenyl-functionalized dendrimers.16 In these
systems, assessment of the biological activity of the pyrenyl-
functionalized dendrimers was not possible due to their
hydrophobic nature, and consequently, only the antiprolifer-
ative activity of the host−guest systems was evaluated. These
studies showed that the host−guest systems inhibit the growth
of both sensitive and cisplatin resistant cancer cells (A2780 and
A2780cisR) with IC50 values comparable to those of the empty
metallaprisms, thus questioning the role of the dendritic
appendages in these systems. Therefore, to determine if a
dendritic eﬀect can be obtained by combining functionalized-
dendrimer and metallacage, water-soluble dendrimers are
necessary.
Herein we present the synthesis of diﬀerent generations of
biodegradable water-soluble dendrimers based on the bis-MPA
monomer unit functionalized by a pyrenyl unit. The aromatic
part of the pyrenyl-functionalized dendrimers may be
encapsulated into the hydrophobic cavity of the hexanuclear
a r e n e r u t h e n i um me t a l l a c a g e s [ R u 6 ( p - c ym e -
ne)6(OO∩OO)3(tpt)2]6+ (OO∩OO = 5,8-dioxydo-1,4-naphta-
quinonato (donq) [1]6+, 6,11-dioxydo-5,12-naphtacenedionato
(dotq) [2]6+; tpt =2,4,6-tri(pyridin-4-yl)-1,3,5-triazine).17 In
contrast to the previously reported pyrenyl-dendrimers in
metallaprism [1]6+,16 the biological activity of both the
dendrimers and of the host−guest systems has been evaluated.
The cytotoxicity of the resulting host−guest systems is
considerably greater than that of the individual hosts and
guests.
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■ RESULTS AND DISCUSSION
Three generations of pyrenyl bis-MPA dendrimers with
acetonide (pyrGn) or alcohol (pyrGn‑OH) (n = 1−3) end-groups
were prepared by two routes (Scheme 1). In the ﬁrst approach,
1-pyrenebutanol reacts with acetonide-2,2-bis(methoxy)-
propionic acid (AMP) to give the ﬁrst generation pyrG1
dendrimer which is then deprotected to obtain pyrG1‑OH. The
same sequence of reactions is used to synthesize the second and
third generation dendrons from the corresponding pyrenyl-
dendritic intermediates. Alternatively, pyrG2 and pyrG3 can also
be synthesized from the bis-MPA dendrimers18 acetonide-Gn-
CO2H (n = 2−3) (bearing a carboxylic group at the focal point
and acetonide groups at the periphery) via esteriﬁcation with 1-
pyrenebutanol. Finally, to obtain the third generation pyrG3
another approach is also used: the previously synthesized
pyrG1‑OH and acetonide-G2-CO2H react together via ester-
iﬁcation. This method allows a better yield in the last step. All
the esteriﬁcations have been performed using N,N′-dicyclohex-
ylcarbodiimide (DCC) as coupling agent and 4-
(dimethylamino)pyridinium p-toluene sulfonate (DPTS) as
catalyst.19 Deprotection of the acetonide was performed with
an acidic resin in methanol as previously described.18 The ﬁrst
method is preferable as it involved 7 steps (Scheme 1), while
the convergent approach18 requires 13 steps (see Supporting
Information). Nevertheless, both methods can be used to
prepare these three generations of pyrenyl-dendrimers.
The esteriﬁcation reaction with 1-pyrenebutanol was
monitored by 1H NMR spectroscopy. The signals of the
aliphatic protons of the pyrenyl part are shifted slightly upﬁeld
after coupling (by up to 0.05 ppm relative to the reactant).
Accordingly, for the divergent approach (the synthesis of pyrGn
from pyrG(n‑1)−OH), the methyl resonances (singlets) are shifted
downﬁeld (by up to 0.1 ppm relative to the previous
generation) as the generation increases with an increase in
their relative integration ratio. Deprotection of the alcohol
groups was also observed by 1H NMR spectroscopy with the
disappearance of the acetonide signals. In addition, the 1H
NMR spectra of the diﬀerent pyrenyl derivatives pyrGn reveal
the inﬂuence of the carbonyl group on the two β methyl groups
attached to the external generation; the methyl resonance
results in two doublets. The proton, Ha, located near the ester
group shifts downﬁeld by up to 0.5 ppm relative to proton Hb,
which is less aﬀected by this inﬂuence. Interestingly, the methyl
protons of the inner generations do not show this behavior
(Figure 1). These diﬀerences can also be seen for the alcohol
free pyrenyl derivatives (pyrGn‑OH).
The inclusion complexes [guest⊂1]6+ and [guest⊂2]6+ were
prepared in two steps (Scheme 2). The dinuclear complexes,
[Ru2(p-cymene)2(donq)Cl2] or [Ru2(p-cymene)2(dotq)Cl2],
are ﬁrst reacted with AgCF3SO3 to aﬀord a dinuclear
intermediate (not isolated), and then 2 equiv of the tpt panels
and 1 equiv of the guest molecule (pyrGn and pyrGn‑OH) are
added to obtain the corresponding inclusion compound. The
resulting hexacationic host−guest systems are isolated in ca.
70% yield as their triﬂate salts [guest⊂1][CF3SO3]6 and
[guest⊂2][CF3SO3]6.
The host−guest properties of [guest⊂1]6+ and [guest⊂2]6+
have been studied in solution. Their stability in a mixture of
water and DMSO (20/80 v/v) was established at room and
elevated temperatures (40 °C). Under these conditions there
are no signs of degradation of the cage, or leaching of the guest
over 24 h, consistent with previous observations.20 Diﬀusion-
ordered NMR spectroscopy (DOSY) measurements in pure
DMSO, at room temperature, were also performed. As an
example, the DOSY spectra of [1]6+ and [pyrG2‑OH⊂1]6+ give
Scheme 1. Synthesis of the Pyrenyl Bis-MPA Dendrimersa
a(i) 1-Pyrenebutanol, DCC, DPTS, dry CH2Cl2; (ii) Dowex H+, MeOH; (iii) AMP, DCC, DPTS, dry CH2Cl2; (iv) acetonide-G2-CO2H, DCC,
DPTS, dry CH2Cl2.
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almost equivalent diﬀusion coeﬃcients (D) with values at ca.
6.3 × 10−10 m2·s−1, thus suggesting the encapsulation of
pyrG2‑OH in the hydrophobic cavity of [1]
6+ and the formation
of a [pyrG2‑OH⊂1]6+ adduct, see Figure 2. The DOSY spectrum
of free pyrG2OH is also shown in Figure 2, and a diﬀusion
coeﬃcient of 0.13 × 10−10 m2·s−1 was estimated, which
conﬁrms the entrapment of the guest molecule in [1]6+. Similar
results were obtained with the metallaprism [2]6+ and the
corresponding [guest⊂2]6+ systems. All diﬀusion coeﬃcients of
the host−guest systems are listed in Table 1.
The stability constants of association (Ka) for these host−
guest systems were estimated by UV−vis titrations of the
pyrenyl derivatives in the presence of the cages at room
temperature in CH2Cl2 or DMSO depending on the solubility
of the dendrimers. The Ka values (Table 1) were obtained using
a nonlinear least-squares ﬁtting method.21 The association
constants are quite high and support the encapsulation of the
guest within the host, which is consistent with the DOSY
measurements. Moreover, these values are comparable with
those obtained with other pyrenyl-functionalized dendrimers
encapsulated by [1]6+.16
The stability of the systems was also evaluated under
biologically relevant conditions using UV−vis spectroscopy.
Absorption spectra of selected [guest⊂1]6+ and [guest⊂2]6+
systems (see Supporting Information) were monitored in a
solution of aqueous RPMI 1640 media (Roswell Park Memorial
Institute medium) containing GlutaMAX (L-glutamine, folic
acid, and NaHCO3). All systems were stable for several hours at
40 °C, with no spectral changes observed. However, after ∼12
h the intensity of the absorption band slowly starts to weaken,
suggesting partial leakage of the guest and breakage of the cage,
and consequently aﬀording smaller fragments in solution.
Similar stability was found with analogous pyrenyl-den-
drimers16 and pyrenyl-functionalized22 molecules encapsulated
by [1]6+ and [2]6+. In addition, UV−vis titrations in RPMI
1640 media of some pyrenyl derivatives in the presence of the
cages were performed to determine their stability constants of
association (see Supporting Information). The Ka values are
smaller than those found in CH2Cl2 or DMSO (Table 1), but
support the idea of having intact host−guest systems under
physiological conditions.
Electronic absorption spectra of the pyrenyl derivatives and
of the inclusion complexes [guest⊂1]6+ and [guest⊂2]6+ were
acquired in the range 200−800 nm in DMSO at 10−4 M
concentration. The UV−vis spectra of the pyrenyl derivatives
are dominated by the absorption of the pyrenyl part (with four
characteristic bands between 290 and 390 nm),23 whereas the
host−guest complexes are characterized by an intense high-
energy band centered at 260 nm and by an absorption band at
around 450 nm assigned to metal-to-ligand charge transfer
process (MLCT).24 The bands observed between 500 and 700
nm are due to the quinonato linkers of the metallaclips.25
Figure 3 illustrates these electronic absorptions with the spectra
of the [guest⊂1]6+ systems. Interestingly, the four characteristic
bands of the pyrenyl part found in the region 290−390 nm are
much stronger in the encapsulated systems than in the spectra
of the free pyrenyl derivatives. For example, the molar
Figure 1. NMR spectra showing the aliphatic protons of pyrGn (n = 1−
3) (in CD2Cl2, 23 °C).
Scheme 2. Encapsulation of Guest in the Metallaprism [1]6+
Figure 2. DOSY spectra of pyrG2‑OH, [1]
6+ and [pyrG2‑OH⊂1]6+ in
DMSO at room temperature.
Table 1. Diﬀusion Coeﬃcients Obtained from the DOSY
NMR Spectra and Association Constants of Pyrenyl-
Containing Dendrimers Estimated from UV−Vis Titrations
(CH2Cl2 or DMSO at 21 °C)
compd
log D
DMSO
Ka (10
4 M−1)
CH2Cl2
Ka (10
4 M−1)
DMSO
[pyrG1⊂1][CF3SO3]6 −9.3 9.5 n.d.
[pyrG2⊂1][CF3SO3]6 −9.1 1.5 n.d.
[pyrG3⊂1][CF3SO3]6 −9.3 13.1 n.d.
[pyrG1‑OH⊂1][CF3SO3]6 −9.3 0.5 0.5
[pyrG2‑OH⊂1][CF3SO3]6 −9.2 n.d. 0.6
[pyrG3‑OH⊂1][CF3SO3]6 −9.8 n.d. 0.6
[pyrG1⊂2][CF3SO3]6 −10.1 2.0 0.4
[pyrG2⊂2][CF3SO3]6 −10.1 0.5 n.d.
[pyrG3⊂2][CF3SO3]6 −10.1 0.2 n.d.
[pyrG1‑OH⊂2][CF3SO3]6 −10.1 9.6 1.7
[pyrG2‑OH⊂2][CF3SO3]6 −10.1 n.d. 3.3
[pyrG3‑OH⊂2][CF3SO3]6 −10.1 n.d. 6.2
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extinction coeﬃcient of the pyrenyl band of free pyrG3‑OH at
316 nm is found at 10 700 L·mol−1·cm−1 and at 34 000 L·
mol−1·cm−1 in [pyrG3‑OH⊂1]6+. This increase of the molar
extinction coeﬃcients of the pyrenyl bands is typical of host−
guest pyrene-containing systems26 and clearly indicates a
synergic eﬀect of the electronic absorptions due to the
association of metallaprisms and pyrenyl derivatives.
Under the conditions of electrospray ionization mass
spectrometry (ESI-MS), the [guest⊂1]6+ and [guest⊂2]6+
systems are remarkably stable. Along with fragmentation
peaks ([{Ru2(p-cymene)2(OO∩OO)} − 2Cl + CF3SO3]+ and
[{Ru2(p-cymene)2(OO∩OO)} − 2Cl + tpt + CF3SO3]+), the
peak envelopes of [guest + 1 + 3CF3SO3]
3+ and of [guest + 2 +
3CF3SO3]
3+ are found for all inclusion systems. These peaks are
assigned unambiguously on the basis of their characteristic Ru6
isotope pattern and conﬁrm the stability of these host−guest
systems. The ESI-MS spectrum of [pyrG2‑OH⊂2][CF3SO3]6 is
shown in Figure 4. A peak envelope corresponding to [pyrG2‑OH
+ 2 + 3CF3SO3]
3+ is observed at m/z 1323.54, with
fragmentation peaks corresponding to [{Ru2(p-cyme-
ne)2(dotq)} − 2Cl + CF3SO3]+ and [{Ru2(p-cymene)2(dotq)}
− 2Cl + tpt + CF3SO3]+ observed at m/z 908.06 and 1221.15,
respectively.
Chem3D simulations,27 used to gain some structural
information, show the dendritic arm extending from the
metallaprism with the pyrenyl moiety being encapsulated inside
the cavity (Figure 5). The [pyrG1⊂2]6+, [pyrG2⊂2]6+, and
[pyrG3⊂2]6+ systems are all estimated to be approximately 4 nm
in length, despite the presence of diﬀerent generations of the
dendritic arm. This observation is consistent with the diﬀusion
coeﬃcients which show similar diﬀusion coeﬃcient for all
host−guest systems.
The antiproliferative activity of the pyrenyl-containing
dendrimers pyrGn and pyrGn‑OH, complexes [1][CF3SO3]6 and
[2][CF3SO3]6, and the host−guest systems [pyrGn⊂1]-
[CF3SO3]6, [pyrGn‑OH⊂1][CF3SO3]6, [pyrGn⊂2][CF3SO3]6,
and [pyrGn‑OH⊂2][CF3SO3]6 were evaluated against human
ovarian A2780 (cisplatin sensitive) and A2780cisR (acquired
resistance to cisplatin) cancer cell lines. Their cytotoxicities, in
comparison to cisplatin, are presented in Table 2.
The nature of the terminal group inﬂuences the water-
solubility of the dendrimers, thus inﬂuencing the cytotoxicity of
the functionalized-pyrenyl dendrimers, with pyrG2‑OH and
pyrG3‑OH showing signiﬁcant cytotoxicities, comparable to
cisplatin, whereas the others, notably the acetonide counter-
parts, are not cytotoxic, presumably due to their poor solubility
in the culture medium. This inactivity of the acetonide
functionalized-pyrenyl dendrimers suggests that, despite a
limited stability over a 72 h period, the decomposition products
formed under biological conditions are not cytotoxic. It is also
worth mentioning that the cytotoxicities on both cisplatin
resistant and cisplatin sensitive cancer cell lines are almost
equivalent for all compounds tested, suggesting a mode of
action and/or detoxiﬁcation diﬀerent from cisplatin. Overall,
the pyrenyl derivatives encapsulated within [1]6+ are slightly
more toxic than their analogues entrapped in [2]6+.
In contrast with the pyrenyl-functionalized poly(aryl ester)
containing cyanobiphenyl groups16a and the pyrenyl poly-
(benzyl ether) containing ﬂexible chains16b encapsulated by
[1]6+, the cytotoxicity of the [guest⊂cage]6+ systems are not
equivalent to the cytotoxicity of the empty cages. Indeed, the
hexaruthenium hosts [1]6+ and [2]6+ exhibit similar cytotox-
Figure 3. UV−vis spectra of inclusion system [guest⊂1][CF3SO3]6 in
DMSO (10−4 M concentration).
F i g u r e 4 . ES I -MS s p e c t r um o f i n c l u s i o n s y s t em
[pyrG2‑OH⊂2][CF3SO3]6 in MeOH with fragmentations and peak
envelope of [pyrG2‑OH + 2 + 3CF3SO3]
3+ (clip = {Ru2(p-
cymene)2(dotq)}).
Figure 5. Simulations of [pyrG1⊂2]6+, [pyrG2⊂2]6+, and [pyrG3⊂2]6+
systems.
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icities to pyrG2‑OH and pyrG3‑OH, and remarkably, when
combined, the resulting host−guest systems are signiﬁcantly
more active than either the host or the guest alone. This
diﬀerence is especially noticeable with [pyrG3‑OH⊂2][CF3SO3]6,
which shows individual IC50 values of 8.7 μM for pyrG3‑OH and
6.5 μM for [2][CF3SO3]6 on A2780cisR cells, while the IC50
value for the host−guest system [pyrG3‑OH⊂2][CF3SO3]6 is 0.8
μM. The enhanced cytotoxicity of the [guest⊂cage]6+ systems
compared to the guest or host alone implies that intact
[guest⊂cage]6+ systems are entering the cells together, and are
responsible for the overall cytotoxicity observed.
■ CONCLUSION
In summary, the entrapment of water-soluble dendrimer guests
within metallaprism hosts leads to apparent enhancements in
cytotoxicity. The host−guest system is also quite stable in
biological media. These features, combined with their potential
to preferentially accumulate in tumors, make them interesting
candidates for further study and development.
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Szoka, F. C. Bioconjugate Chem. 2002, 13, 453−461.
(15) Kojima, C.; Kono, K.; Maruyama, K.; Takagishi, T. Bioconjugate
Chem. 2000, 11, 910−917.
(16) (a) Pitto-Barry, A.; Barry, N. P. E.; Zava, O.; Deschenaux, R.;
Dyson, P. J.; Therrien, B. Chem.Eur. J. 2011, 17, 1966−1971.
(b) Pitto-Barry, A.; Barry, N. P. E.; Zava, O.; Deschenaux, R.;
Therrien, B. Chem.Asian J. 2011, 6, 1595−1603.
(17) (a) Barry, N. P. E.; Therrien, B. Eur. J. Inorg. Chem. 2009,
4695−4700. (b) Freudenreich, J.; Barry, N. P. E.; Süss-Fink, G.;
Therrien, B. Eur. J. Inorg. Chem. 2010, 2400−2405. (c) Schmitt, F.;
Freudenreich, J.; Barry, N. P. E.; Juillerat-Jeanneret, L.; Süss-Fink, G.;
Therrien, B. J. Am. Chem. Soc. 2012, 134, 754−757.
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